The FDA just released details on the July 21 Advisory Panel hearing on whether Dexcom’s G5 CGM should be officially approved for dosing insulin. The meeting is open to the public, and anyone interested can (i) submit a written comment to the FDA; (ii) attend the meeting; and (iii) request to give an oral presentation to the panel.